Integral Molecular, a company discovering antibodies against multipass membrane proteins, has launched fully optimised, high-affinity lead monoclonal antibodies against Claudin 18.2 (CLDN18.2), a structurally complex oncology target overexpressed on various solid tumours, it was reported on Tuesday.
The CLDN18.2 antibodies found using the firm's MPS antibody discovery platform are ready to progress towards preclinical studies and are completely humanised, unlike the Phase 3 clinical benchmark.
Integral Molecular showcased its CLDN18.2 MAbs at the virtual PEGS Europe (Protein & Antibody Engineering Summit) earlier this month. CLDN18.2 is expressed in multiple cancers, including lung, pancreatic and oesophageal cancers, but indicates limited expression in healthy adult tissue.
Ross Chambers, VP of Antibody Discovery, said, 'The structural complexity of CLDN18.2 and the widespread expression of closely related family members has made discovery of highly specific antibodies against CLDN18.2 challenging. Our exquisitely specific, picomolar affinity lead candidates show stronger binding than the most advanced clinical antibody and are a testament to the ability of our platform to yield antibodies against difficult targets.'
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886